InsiderStreet Equity Research

Produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation for any investor. Do not rely on it for any investment decision.

Last Close

$384.02

2026-10-16

Market Cap

$27.0B

Volume

0.5M

52-Wk High

$386.22

52-Wk Low

$223.83

Trailing PE

48.8

P/S

8.12

Gross Margin

36.8%

Net Margin

17.0%

ROE

19%

ROIC

16%

Piotroski

8/9

Altman Z

18.2

1-Yr Return

+43.8%

5-Yr Return

+168.9%

West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies. This segment further supplies ancillary services such as specialized films, protective coatings, cleaning, precision vision inspection, and sterilization processes to elevate the quality of packaging components. Innovative drug containment options, like Crystal Zenith â a cyclic olefin polymer used in vials, syringes, and cartridges â and user-friendly self-injection devices are also key offerings. Additionally, it provides a suite of integrated support services covering analytical laboratory analysis, primary packaging assistance during the pre-approval stage, engineering development, regulatory guidance, and post-purchase technical support. Its clientele primarily includes manufacturers of biologic, generic, and other pharmaceutical products. In contrast, the Contract-Manufactured Products division focuses on the design, production, and automated assembly of various devices for surgical, diagnostic, ophthalmic, and general drug delivery applications, alongside consumer items. This segment caters to pharmaceutical, diagnostic, and medical device manufacturers. The company's offerings reach customers worldwide through a dedicated sales team, an extensive distribution network, and partnerships with contract sales agents and regional distributors. Established in 1923, West Pharmaceutical Services, Inc. is headquartered in Exton, Pennsylvania.

SectorHealthcareIndustryMedical - Instruments & SuppliesExchangeNYSEMarket Cap$27.0BEmployees10,800 (SEC-filed)CEOMichel LagardeIPO1980-03-17CountryUS

530 Herman O. West Drive, Exton, PA 19341-1147 · Tel 610 594 2900 · westpharma.com

INSIDERSTREET SCORE72 / 100Street mean $420.00 (4 analysts, last qtr) — their number, not ours

INSIDER CONSENSUS SIGNALROUTINE SELLING — LOW SIGNAL$5M sold / 6 mo, zero open-market buys

1 Year vs S&P 500 · WST +43.8% · S&P 500 +15.9% · spread +27.9pp

7 Years vs S&P 500 · WST +168.9% · S&P 500 +189.9% · spread -21.0pp

Both charts indexed to 100 at the start of their window and drawn on a single shared scale, so the gap to the benchmark is the gap you see. Adjusted closes throughout.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

INSIDERSTREET
SCORE72of 100

Score Breakdown

Profitability	67/100
Growth	61/100
Momentum	84/100
Quality	88/100
Earnings Quality	72/100
Balance Sheet	90/100
Value	41/100
Risk (safety)	100/100
Overall	71.5/100

Each component is a diagnostic reading on its own 0-100 scale. The overall score is computed separately from the underlying financials and is not the average of the rows above — components are not equally weighted and three of them (Momentum, Value, Risk) are derived partly from price rather than from the business.

Peer Comparison — IS Score

Symbol	IS Score
MDLN	43
RMD	82
HOLX	56
SOLV	37
BDX	43
BAX	32
WST	72

IS Score Trend — quarterly

14 quarters, 23 Q1 to 26 Q2. Peak 74 in 26 Q1, latest 72 — -2 since. Fell in 1 of the last 4 quarters. Dashed line marks 40 on the 0-100 scale.

BUSINESS QUALITY72 / 100IS Score 71.5 / 100 · -2.0 from peak of 74

Fundamental factor model, quarterly. Measures how the business is doing - not where the price is going.

PRICE STRUCTUREBULLISHTechnical Score 88 / 100 · Power +77 · 22 of 22 indicator votes bullish

Vote share across trend, momentum, volume, volatility and pattern families. Describes where the price is, not where it is going.

Both readings sit above the midpoint — business quality at 72 and price structure at 88 out of 100 — so they are not in conflict. The fundamentals and the tape are saying the same thing, which is the case in which either one alone would have been enough.

Trigger	Where it stands now	What it would mean
IS Score reaches 75 and holds two consecutive quarters	now 71.5	would move us up one band
IS Score stops falling - one quarter higher than the prior	last four: 65 → 67 → 74 → 72	the direction matters more than the level
Technical vote share back above 50%	now 100%	price structure no longer broken
Institutional holder count rises two quarters running	peak 838 → now 838	fewer institutions willing to hold is our clearest warning

We publish these so the view can be shown to be wrong. If none of them move and our reading does, we owe you an explanation.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

This page is InsiderStreet's own reading, produced from the data in the rest of this document. It is not a price target and not investment advice. Analyst consensus and street price targets appear later under their own heading and are the street's numbers, not ours.

Site Convergence Score1 of 4top 66% of 29,420 symbols

Sources Aligned— of 3independent disclosures

Congress (180d)0 buysnone disclosed

Insider Buys (180d)0none disclosed

ETF Funds (30d)1082 up / 882 downnet +200 funds

Congressional and insider figures are disclosed purchases in the trailing 180 days; ETF figures are COUNTS OF FUNDS whose holding changed in 30 days, not dollars. Coincidence of separate disclosures, not coordination. An absent source means nothing qualifying was disclosed in its window.

Institutions holding — 12 quarters

Peak 838 · latest 838 (+0 from peak).

Quarter	Holders	13F shares	Value	Reported own%	Guard
2026 Q2	838	71.1M	$24.5B	100.4%	ex-outlier 91.0%
2026 Q1	755	71.1M	$16.8B	100.4%	ex-outlier 90.8%
2025 Q4	805	69.5M	$18.3B	98.2%
2025 Q3	761	69.2M	$17.4B	97.7%
2025 Q2	737	70.1M	$14.8B	99.0%
2025 Q1	719	69.9M	$15.1B	98.7%
2024 Q4	749	69.9M	$22.2B	98.7%
2024 Q3	734	68.6M	$19.8B	96.9%
2024 Q2	782	68.3M	$21.5B	96.5%
2024 Q1	784	68.6M	$25.8B	96.8%
2023 Q4	787	68.7M	$22.9B	97.1%
2023 Q3	762	68.7M	$24.2B	97.0%

How to read ownership above 100%. A 13F reports the positions a manager has investment discretion over, and where two or more managers share discretion over the same block, each one reports it. Summed across filers, the total can therefore exceed the shares actually outstanding without anything being wrong. We publish the figure as filed rather than netting it down, and flag separately any quarter where the arithmetic is not merely high but impossible.

Why 2026-06 reads 100.37%. Institutions cannot hold more of a company than exists. The reported 71.1M shares exceed the 70.8M outstanding, and a single filer accounts for the excess: BlackRock, Inc. reports 6,651,784 shares against 6,836,714 the prior quarter, a 1x jump, which alone would be 9.4% of the company. Excluding that filing, ownership is 91.0%. We publish both figures. 13F filings are due 45 days after quarter end and amendments keep arriving after that, so the newest quarter is provisional by construction - this is what an unsettled quarter looks like.

Why 2026-03 reads 100.41%. Institutions cannot hold more of a company than exists. The reported 71.1M shares exceed the 70.8M outstanding, and a single filer accounts for the excess: BlackRock, Inc. reports 6,836,714 shares against 6,599,735 the prior quarter, a 1x jump, which alone would be 9.7% of the company. Excluding that filing, ownership is 90.8%. We publish both figures. 13F filings are due 45 days after quarter end and amendments keep arriving after that, so the newest quarter is provisional by construction - this is what an unsettled quarter looks like.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Insider	Role	Date	Type	Shares	Value	Post-Txn Owned
Haugen Janet Brutschea	director	2026-09-30	A-Award	44	—	351
Favorite Annette F	Sr. VP & Chief HR Officer	2026-09-15	EXERCISE	2,524	$0.23M	24,342
Favorite Annette F	Sr. VP & Chief HR Officer	2026-09-15	SELL	2,524	$0.92M	21,818
Favorite Annette F	Sr. VP & Chief HR Officer	2026-09-15	EXERCISE	2,524	$0.23M	0
Favorite Annette F	Sr. VP & Chief HR Officer	2026-09-14	EXERCISE	2,500	$0.22M	24,318
Favorite Annette F	Sr. VP & Chief HR Officer	2026-09-14	SELL	2,500	$0.89M	21,818
Favorite Annette F	Sr. VP & Chief HR Officer	2026-09-14	EXERCISE	2,500	$0.22M	2,524
Favorite Annette F	Sr. VP & Chief HR Officer	2026-09-11	SELL	2,500	$0.86M	21,818

6-mo decomposition (Form 4)	Txns	Shares	Value	Signal weight
S — Open-market sales	6	13,737	$4.7M	Counted
M — Exercises (paired A/D)	11	24,791	$1.5M	None — mechanics
F — Tax withholding	4	3,328	$1.2M	None — compensation
P — Open-market purchases	0	0	$0	Counted — none occurred

Monthly Net Insider Flow (000 shares)

Net of acquisitions minus dispositions, all Form 4 types.

Signal Summary

SignalRoutine Selling — Low Signal

Open-Market Sells$4.7M6 txns / 6 mo

Open-Market Buys$0.0M0 txns / 6 mo

ClusterNone active3+ insiders / 21 days

Filed	Filer	Shares registered	Est. proceeds
2026-05-07	Hofmann Thomas W	3,384	$1.1M
2024-08-06	Green Eric Mark	30,732	$9.4M
2024-05-10	Hofmann Thomas W	617	$0.2M
2024-05-07	Green Eric Mark	66,000	$24.3M
Trailing 12 mo	1 filings	3,384	$1M

Filed	Form	Reporting person	% of class	Shares
2026-08-06	SCHEDULE 13G	Abigail P. Johnson	5.00%	3.6M sh
2026-04-30	SCHEDULE 13G	Vanguard Capital Management	7.48%	5.4M sh
2026-04-29	SCHEDULE 13G	Vanguard Portfolio Management	5.69%	4.1M sh
2026-03-27	SCHEDULE 13G/A	The Vanguard Group	—	exit/reporting change

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Member	Chamber	Trade	Size band	Traded	Disclosed
Lisa McClain	House	SELL	$1,001 - $15,000	2025-07-22	2025-08-13
Lisa McClain	House	BUY	$1,001 - $15,000	2025-06-17	2025-08-13
Lisa C. McClain	House	BUY	$1,001 - $15,000	2025-06-16	2025-08-13
Tommy Tuberville	Senate	SELL	$1,001 - $15,000	2022-03-30	2022-04-08
Tommy Tuberville	Senate	SELL	$1,001 - $15,000	2022-03-30	2022-04-07
Thomas Hawley Tuberville	Senate	SELL	$1,001 - $15,000	2022-03-30	2022-04-07

House 12-Mo0 tradesNone purchases

Senate 12-Mo0 tradesNone purchases

CoverageSTOCK Act filings30-45 day disclosure lag

13F Filers (last complete Q)755

13F Shares71M100.4% of shares out

New / Closed89 / 125positions, QoQ

Increased / Reduced265 / 281positions, QoQ

Put/Call (13F)0.71option positions

Free Float99.3%70M sh

2.8 · Largest Reporting 13F Managers

Manager	Shares	Value
Border To Coast Pensions Partnersh	219,390	$81M
Birch Hill Investment Advisors Llc	158,911	$59M
Seilern Investment Management Ltd	120,729	$45M
Ninety One Uk Ltd	86,378	$32M
Mccollum Christoferson Group Llc	63,775	$14M
Assenagon Asset Management S.A.	51,639	$19M

EDGAR 13F holdings as of 2026-09-30; filer values normalized to dollars.

2.9 · Top ETF & Fund Ownership

Fund	Weight	Position
VITSX	0.0%	$828M
VTSAX	0.0%	$828M
VSMPX	0.0%	$828M
VTI	0.0%	$828M
VFFSX	0.0%	$685M
VFIAX	0.0%	$685M

13F Filers Holding WST — quarterly

Institutional Put/Call — quarterly

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Daily short-sale volume as % of volume reported in FINRA's short-sale file — a flow measure, not short interest; dashed = 50-day average.

Latest Session62.7%2026-10-15

20-Day Avg52.9%50-day 55.6%

TrendFalling20d vs 50d

By Market CenterQ: 62% · N: 64% · B: 90%latest session

Weekly Notional ($B)

Where WST Trades in the Dark

ATS Venue (4-wk)	Shares	Avg trade
Incr Intelligent Cross Llc	1.6M	27 sh
Ubsa Ubs Ats	1.4M	32 sh
Ebxl Level Ats	0.8M	19 sh
Sgmt Sigma X2	0.7M	22 sh
Mstx Ms Trajectory Cross (Ats-1)	0.7M	27 sh
Mlix Instinct X	0.6M	32 sh

Where a dollar of West Pharmaceutical Services, Inc. revenue goes. All values FY2025 filings, live.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Region	Revenue	Share
UNITED STATES	$1.3B	43%
Other Europe Countries	$451M	15%
GERMANY	$380M	12%
Other Countries	$353M	11%
IRELAND	$333M	11%
FRANCE	$227M	7%

WST (live moat model)Peer median: MDLN · RMD · HOLX · SOLV · BDX

Component scores from the live moat model. Peer median illustrative.

Moat score 54/100 — Weak; primary source Efficient Scale.

3.8 · Employees (SEC filings)

Officer	Title
Robert W. McMahon	Senior Vice President & Chief Financial Officer
Eric Green	Non-Independent Chair of the Board, President & Chief Executive Officer
Devesh Mathur	Senior Vice President & Chief Technology Officer
Shane Campbell	SVP & Chief Proprietary Segment Officer

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Revenue ($B)

EPS ($) — GAAP diluted actual, street-basis estimate

Actual bars are GAAP diluted EPS from the filed income statement; the lighter forward bars are street-basis consensus. The two are different measures and are not comparable quarter to quarter.

Quarterly EPS — Actual vs. Consensus

Beats (>2%)6 of 6recent quarters

Avg Surprise+18.4%

Next Report2026-10-29

Income Quality1.17OCF ÷ net income

Beat Rate—%0 of 0 quarters

Current Streak0longest 0

Avg EPS Surprise—%median —%

Surprise Trend—last 4 vs prior 4

Period	EPS est.	EPS actual	EPS surprise	Rev est. ($M)	Rev actual ($M)	Rev surprise

Announcement dates to . Consensus as it stood at each report. Revenue surprise shown where both estimate and actual are filed. A beat record is history, not a forecast.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Profit Margins (%)

Revenue by Segment — Stacked

Live segmentation data.

YoY Growth Heatmap — Income Lines

YoY growth	FY21	FY22	FY23	FY24	FY25
Revenue	+31.9%	+1.9%	+2.3%	-2.0%	+6.3%
Gross profit	+52.8%	-2.9%	-0.5%	-11.5%	+10.1%
Operating income	+81.1%	+0.6%	-6.9%	-16.4%	+3.8%
Net income	+91.2%	-11.5%	+1.3%	-17.0%	+0.2%

$B · FY ends	FY21	FY22	FY23	FY24	FY25
Revenue	2.8	2.9	3.0	2.9	3.1
Cost of revenue	1.7	1.7	1.8	1.9	2.0
Gross profit	1.2	1.1	1.1	1.0	1.1
R&D expense	0.1	0.1	0.1	0.1	0.1
SG&A expense	0.4	0.3	0.4	0.3	0.4
Operating income	0.8	0.8	0.7	0.6	0.6
EBITDA	0.9	0.8	0.8	0.7	0.7
D&A	0.1	0.1	0.1	0.2	0.1
Pretax income	0.8	0.7	0.7	0.6	0.6
Income tax	0.1	0.1	0.1	0.1	0.1
Net income	0.7	0.6	0.6	0.5	0.5
Diluted EPS ($)	8.67	7.73	7.88	6.69	6.80
Diluted shares (M)	76	76	75	74	73

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Operating CF$1B

CapEx$0B

Free cash flow$0B

SBC$0B

Buybacks$0B

Net cash change$0B

Balance Sheet — Full

$B	FY22	FY23	FY24	FY25
Cash & equivalents	0.9	0.9	0.5	0.8
ST investments	0.0	0.0	0.0	0.0
Receivables (net)	0.5	0.5	0.6	0.6
Total current assets	1.9	1.9	1.5	2.0
PP&E (net)	1.3	1.5	1.7	0.0
Goodwill + intangibles	0.1	0.1	0.1	0.1
Total assets	3.6	3.8	3.6	4.3
Accounts payable	0.2	0.2	0.2	0.3
Short-term debt	0.0	0.1	0.0	0.0
Deferred revenue	0.1	0.0	0.0	0.0
Total current liabilities	0.5	0.7	0.6	0.7
Long-term debt	0.2	0.1	0.2	0.3
Total liabilities	0.9	0.9	1.0	1.1
Shareholders' equity	2.7	2.9	2.7	3.2

Cash Flow Statement — Full

$B	FY22	FY23	FY24	FY25
Net income	0.6	0.6	0.5	0.5
D&A	0.1	0.1	0.2	0.2
Stock-based compensation	0.0	0.0	0.0	0.0
Working capital change	(0.0)	(0.0)	0.0	0.1
Operating cash flow	0.7	0.8	0.7	0.8
Capital expenditures	(0.3)	(0.4)	(0.4)	(0.3)
Investing cash flow	(0.3)	(0.4)	(0.4)	(0.3)
Buybacks	(0.2)	(0.5)	(0.6)	(0.1)
Dividends paid	(0.1)	(0.1)	(0.1)	(0.1)
Debt issuance / (repay)	(0.0)	(0.0)	(0.0)	(0.0)
Financing cash flow	(0.3)	(0.5)	(0.6)	(0.2)
Free cash flow	0.4	0.4	0.3	0.5

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet Structure ($B)

Cash Generation vs Capex ($B)

Left: what the balance sheet is made of — the gap between the assets bar and the liabilities bar is book equity. Right: whether the capex bar is covered by the operating-cash bar; where it is not, the difference was funded externally and free cash flow goes negative.

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
PROFITABILITY
ROE	31.6%	23.3%	21.3%	17.7%	16.9%	19%
ROA	21.7%	16.9%	15.9%	13.2%	12.5%	13.9%
ROIC	34.2%	30.1%	25.4%	19.6%	17.7%	15.8%
Gross margin	41.5%	39.5%	38.4%	34.6%	35.9%	36.8%
Operating margin	26.8%	26.5%	24.1%	20.6%	20.1%	20.6%
Net margin	23.4%	20.3%	20.1%	17.0%	16.1%	17.0%
EBITDA margin	31.1%	28.0%	28.6%	25.7%	23.5%	26.2%
FCF margin	11.7%	15.2%	14.1%	9.6%	15.3%	—
VALUATION
P/E	53.59	30.13	44.25	48.84	40.52	48.8
P/B	15.18	6.57	9.12	8.97	6.30	9.1
P/S	12.53	6.12	8.90	8.32	6.51	8.12
P/FCF	107.27	40.17	63.35	87.06	42.66	61.9
EV/EBITDA	39.82	21.14	30.47	32.07	25.29	30.9
EV/Revenue	12.37	5.92	8.72	8.26	6.39	8.1
Earnings yield	1.9%	3.3%	2.3%	2.0%	2.5%	2.08%
FCF yield	0.9%	2.5%	1.6%	1.1%	2.3%	1.62%

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
LEVERAGE & SOLVENCY
Current ratio	2.93	3.70	2.88	2.79	3.02	2.82
Quick ratio	2.30	2.90	2.24	2.11	2.34	2.12
Debt / equity	0.14	0.12	0.11	0.11	0.13	0.10
Debt / assets	9.8%	8.8%	8.1%	8.4%	9.8%	7.7%
Net debt / EBITDA	-0.50	-0.71	-0.65	-0.24	-0.48	-0.14
Interest coverage	90.15	90.41	80.32	159.24	1007.67	—

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
EFFICIENCY
Asset turnover	0.93	0.83	0.79	0.77	0.78	0.82
Receivables turnover	6.48	5.79	5.79	5.43	5.46	4.7
DSO (days)	56	63	63	67	67	78
DPO (days)	49	47	46	47	46	44
Cash conversion cycle	84	99	102	99	97	112
GROWTH (YoY)
Revenue growth	31.9%	2.0%	2.2%	-1.9%	6.3%	—
Net income growth	91.2%	-11.5%	1.3%	-17.0%	0.2%	—
EPS growth	90.4%	-10.5%	2.1%	-15.5%	1.6%	—
FCF growth	10.9%	32.9%	-5.7%	-33.3%	69.6%	—
PER SHARE ($)
EPS (diluted, TTM)	8.66	7.75	7.91	6.69	6.79	7.98
Book value / share	30.57	35.51	38.41	36.39	43.69	42.23
Revenue / share	37.05	38.18	39.33	39.25	42.28	46.98
FCF / share	4.33	5.81	5.53	3.75	6.45	6.17
Cash / share	9.98	11.83	11.39	6.58	10.88	6.16
SHAREHOLDER RETURN & SCORES
Buyback yield	0.4%	1.3%	1.7%	2.4%	0.7%	0.00%
Altman Z-Score	24.81	14.41	19.68	18.20	13.96	18.2
Piotroski F-Score	7	6	6	5	6	8/9
Beneish M-Score	-2.17	-2.58	-2.76	-2.53	-1.24	-3.79

Model	Score	Zone	Note
Piotroski F-Score	8 / 9	Strong
Altman Z-Score	18.2	Safe (>2.99)	Safe
Income quality	1.17	Cash-backed	OCF ÷ net income
Beneish M-Score	-3.79	Non-manipulator	vs −2.22 threshold

DuPont Decomposition (TTM)	Value
Tax burden	0.81
Interest burden	1.01
Operating margin	20.7%
Asset turnover	0.83×
Financial leverage	1.36×
= ROE	19%

Growth Quality (live)	Value
Revenue stability	0.90
Earnings stability	0.07
Earnings persistence	0.94
Revenue CAGR 3y	5.1%
EPS CAGR 3y	4.8%
FCF CAGR 3y	3.3%

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Buyback Yield0.00%

Dividend Yield0.23%

Total Shareholder Return0.23%cash yield

SBC / Revenue1.0%dilution pressure

Company	Mkt cap	P/E	ROE	Net margin	Rev growth	Piotroski	1-yr ret
MDLN	$31.5B	41.8	3%	0.8%	—	4/9	-12.3%
RMD	$33.6B	22.9	24%	26.2%	+9.9%	7/9	-11.3%
HOLX	$17.0B	30.3	11%	17.1%	+2.2%	6/9	+13.2%
SOLV	$14.6B	10.4	34%	4.2%	-0.9%	7/9	+20.1%
BDX	$52.2B	57.8	4%	7.6%	-2.6%	6/9	—
BAX	$13.1B	-12.4	-16%	4.3%	+5.4%	3/9	—
RGEN	$11.1B	237.1	2%	2.5%	+16.5%	8/9	—
AVTR	$11.1B	-19.6	-10%	2.3%	-1.6%	6/9	—

1-yr returns computed from adjusted price history; peers without a tracked series show —.

Buy

17 Analysts

Str Sell (0)Sell (1)Hold (2)Buy (14)Str Buy (0)

Mean Target (qtr)$420.004 targets

Target vs. Price+9.4%last-quarter mean

Next Report2026-10-29street $2.20

Consensus estimates	Revenue mean	High / Low	EPS mean	High / Low	# EPS est.
FY2026	$3.38B	$3.39B / $3.32B	$8.98	$9.05 / $8.88	10
FY2027	$3.58B	$3.61B / $3.53B	$10.03	$10.34 / $9.50	11
FY2028	$3.85B	$3.98B / $3.71B	$11.46	$12.61 / $10.43	5

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Street Price Target — Trajectory

Window	Avg Target	vs. Price	# Targets
Last Month	$420.00	+9.4%	2
Last Quarter	$420.00	+9.4%	4
Last Year	$359.62	-6.4%	21
All Time	$350.41	-8.8%	29

Rolling mean of published targets vs. last close $384.02. Aggregated from StreetInsider, Benzinga.

Third-Party Composite Rating

B+

DCF

3/5

ROE

5/5

ROA

5/5

Debt/Eq

3/5

P/E

1/5

P/B

1/5

Independent quant composite as of 2026-10-16; components scored 1–5 (5 best). Shown for contrast with the InsiderStreet Score — methodologies differ.

WST +43.8% vs S&P 500 +15.9% — spread +27.9pp

Sector — XLV +24.2%

Peer Set — indexed to 100

All series indexed to 100 at the start of the window, adjusted closes.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Candlesticks with SMA 20/50 overlay, Bollinger (20,2σ) band, volume, and Wilder RSI(14) — computed from live daily OHLCV.

Moving Average	Value	Distance	% Distance	Signal
SMA 20	$371.59	+12.43	+3.35%	Above
SMA 50	$358.14	+25.88	+7.23%	Above
SMA 200	$307.25	+76.77	+24.99%	Above
EMA 9	$374.75	+9.27	+2.47%	Above
EMA 21	$369.58	+14.44	+3.91%	Above
EMA 50	$360.39	+23.63	+6.56%	Above
EMA 200	$321.55	+62.47	+19.43%	Above

Series and readings from the nightly technical-indicator history — identical data to the site's ribbon chart. Supertrend segments colored by direction.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

TECHNICAL VERDICTBULLISHPower Score +7722 of 22 indicator votes bullish

Family Scores (site weights)

Trend 30%100

Momentum 25%100

Volume 20%88

Volatility 10%83

Patterns 15%50

This Week100% bullishof 11 price-based votes

4 Weeks Ago100%+0 pts since

12 Weeks Ago55%+45 pts since

ReadStabilizingweek-over-week trajectory

Price vs SMA 20$371.59

Price vs SMA 50$358.14

Price vs SMA 200$307.25

EMA 9/21 Cross374.8/369.6

SMA 50/200Golden

ADX DirectionADX 36

Supertrend$357

Parabolic SAR$360

SMA Slope1.080

RSI65.5

Stochastic K/D85/70

StochRSI K/D77/58

Williams %R-10

CCI190

TSI vs Signal18.8

CMO30.9

ROC5.16%

OBV SignalAccum

Chaikin MF0.030

MFI63

Force Index1M

Elder Ray Bull17.06

RSI (14)30 oversold · 70 overbought

Stochastic %Kvs %D 70

Money Flowvolume-weighted RSI

ADXtrend strength · <20 weak

Williams %Rinverted scale

Level	Value	Level	Value
Pivot / R1 / R2	$381.17 / $386.25 / $389.47	S1 / S2	$377.95 / $372.87
Bollinger (20,2)	$359.68 – $383.51	Squeeze	ON
52-wk range	$223.83 – $386.64	Off 52-wk high	-0.7%
ATR (14)	$8.75 (2.3%)	Historical vol	22.2%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

-0.4%Jan50%

-1.3%Feb50%

+4.3%Mar71%

+2.7%Apr70%

+0.4%May55%

+1.9%Jun65%

+3.7%Jul65%

+0.5%Aug60%

-0.4%Sep40%

+1.5%Oct65%

+2.8%Nov70%

+2.1%Dec70%

Sample: 20 years — treat short histories as suggestive, not statistical.

Computed from live weekly prices	WST	S&P 500
Weekly volatility (σ, 1y)	4.70%	1.83%
Best / worst week (1y)	+15.0% / -9.3%	—
Max drawdown (5y, monthly)	-52.7%	—
1-week VaR (95%)	-7.2%	—
Beta (5y)	1.14	1.00

WST EQUITY WEATHER (LIVE)PARTLY CLOUDY · +25

Trend+44

Momentum+49

Volume+34

Volatility-30

Breadth-30

MARKET REGIME (2026-10-16)NEUTRAL

VIX19.99Normal

Dow TheoryConfirmed Bearish

SPY / QQQ TSI7.2 / 4.7trend strength

Sector Strength46/100breadth average

Average sentiment of 412 stories, weekly buckets, −1 to +1.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Overall+24.8+35.1 vs industry

Trend+44.4+43.7 vs industry

Momentum+48.6+49.8 vs industry

Volume+34.0+16.9 vs industry

Reading	WST	Medical - Instruments & Supplies n=284	Healthcare n=5,272	All US symbols n=70,435
Overall	+24.8	-10.3	-24.0	-20.5
Trend	+44.4	+0.7	-25.6	-21.3
Momentum	+48.6	-1.1	-28.5	-15.8
Volume	+34.0	+17.1	-25.0	-3.8

Trend, momentum and volume are computed per company. Volatility and breadth are market-regime values shared by every symbol in the universe, so they are reported once under Market Regime rather than compared here - a company cannot differ from its sector on a constant.

Executive	Total comp	Structure
Robert W. McMahon SVP, Chief Financial Offic	$11.8M	53% equity+incentive
Eric M. Green President and CEO, Chair of Bo	$7.2M	67% equity+incentive
Shane A. Campbell SVP, Chief Proprietary Seg	$2.4M	69% equity+incentive
Bernard J. Birkett Former SVP, Chief Financi	$2.1M	51% equity+incentive
Annette F. Favorite SVP, Chief Human Resourc	$1.4M	57% equity+incentive

Pillar (live disclosure scores)	Score
Environmental	83
Social	78
Governance	78
Composite ESG	80

Composite ESG Trend

Filed	8-K contents	Items
2026-07-23	Earnings Release; Regulation FD; Exhibits	2.02,7.01,9.01
2026-07-14	Material Agreement; Exhibits	1.01,9.01
2026-06-01	Officer/Director Change; Regulation FD; Exhibits	5.02,7.01,9.01
2026-05-20	Exhibits	9.01
2026-05-05	Shareholder Vote; Exhibits	5.07,9.01
2026-04-23	Earnings Release; Regulation FD; Exhibits	2.02,7.01,9.01
2026-03-09	Departure/Election of Directors; Appointment of Officers; Regulation F	5.02,7.01,9.01
2026-02-12	Results of Operations and Financial Condition; Regulation FD Disclosur	2.02,7.01,9.01

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Methodology. Every figure originates in InsiderStreet's production data layer and is computed deterministically by the same engines that power insiderstreet.ai. This factsheet contains no model-written text. Sections without underlying data are omitted rather than estimated.

DISCLOSURES. This document is produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation tailored to any person. Data is sourced as of the dates shown and may no longer be current. InsiderStreet.ai is not a registered investment adviser or broker-dealer. Investing involves risk, including loss of principal. Past performance does not guarantee future results. Do not make any investment decision based on this document. © 2026 InsiderStreet.ai — all rights reserved. Redistribution prohibited.

Data domain	Source	Coverage for this report
Price & volume	market_db.historical_prices	52 rows
Fundamentals	income_statements_annual	6 rows · 2020 to 2025
Reported vs consensus	fact/earnings_calendar	24 rows · 2020-10-22 to 2026-07-23
Analyst estimates	dim/forward_estimates	3 rows · 2026-12-31 to 2028-12-31
Institutional ownership (13F)	holdings_db.institutional_ownership_summary	110 rows · 1999 to 2026
Insider transactions (Form 4)	edgar/form4	12 rows · 2026-09-08 to 2026-09-30
Proposed sales (Form 144)	edgar/form144	1 record
Beneficial ownership (13D/G)	edgar/13dg	4 rows · 2026-03-27 to 2026-08-06
Short-sale volume (FINRA)	edgar/short_volume_daily	60 rows · 2026-07-23 to 2026-10-15
Dark pool (ATS, tier 1)	edgar/darkpool_weekly	12 rows · 2026-06-15 to 2026-08-31
ETF & fund holding	etf_holdings_changelog (30d)	1 record
Peer set	stock_peers_dynamic	8 rows
Industry medians	industry_medians	1 record
Congressional trades	congress_db (House + Senate)	1 record
ESG	fact/esg_disclosures	1 record

Method. Every figure in this factsheet is looked up from a named field computed in code. It contains no model-written text.

Not covered. Short interest as a percent of float and days-to-cover are not in this data set — the short-sale figures above are FINRA volume, a flow, and cannot support squeeze or covering analysis. Options positioning and intraday data are also absent. 13F ownership is filed 45 days after quarter end and congressional trades are disclosed on a lag, so both describe a past position, not a current one.